230 related articles for article (PubMed ID: 20393310)
1. Myriad Genetics: In the eye of the policy storm.
Gold ER; Carbone J
Genet Med; 2010 Apr; 12(4 Suppl):S39-70. PubMed ID: 20393310
[TBL] [Abstract][Full Text] [Related]
2. Impact of gene patents and licensing practices on access to genetic testing for inherited susceptibility to cancer: comparing breast and ovarian cancers with colon cancers.
Cook-Deegan R; DeRienzo C; Carbone J; Chandrasekharan S; Heaney C; Conover C
Genet Med; 2010 Apr; 12(4 Suppl):S15-38. PubMed ID: 20393305
[TBL] [Abstract][Full Text] [Related]
3. Comment on "Myriad genetics: in the eye of the policy storm".
Palombi L
Genet Med; 2010 Jul; 12(7):471; author reply 471-2. PubMed ID: 20631548
[No Abstract] [Full Text] [Related]
4. Direct to confusion: lessons learned from marketing BRCA testing.
Matloff E; Caplan A
Am J Bioeth; 2008 Jun; 8(6):5-8. PubMed ID: 18726769
[TBL] [Abstract][Full Text] [Related]
5. Social contract theory and just decision making: lessons from genetic testing for the BRCA mutations.
Williams-Jones B; Burgess MM
Kennedy Inst Ethics J; 2004 Jun; 14(2):115-42. PubMed ID: 15281186
[TBL] [Abstract][Full Text] [Related]
6. Gene patents and licensing: case studies prepared for the Secretary's Advisory Committee on Genetics, Health, and Society.
Cook-Deegan R; Heaney C
Genet Med; 2010 Apr; 12(4 Suppl):S1-2. PubMed ID: 20393303
[TBL] [Abstract][Full Text] [Related]
7. Take off your genes and let the doctor have a look: why the Mayo and Myriad decisions have invalidated method claims for genetic diagnostic testing.
Bergin C
Am Univ Law Rev; 2013; 63(1):173-217. PubMed ID: 25335200
[TBL] [Abstract][Full Text] [Related]
8. Myriad Genetics embroiled in breast-cancer data fight - again.
Check Hayden E
Nature; 2016 May; 533(7604):449. PubMed ID: 27225096
[No Abstract] [Full Text] [Related]
9. Do patents impede the provision of genetic tests in Australia?
Nicol D; Liddicoat J
Aust Health Rev; 2013 Jun; 37(3):281-5. PubMed ID: 23702081
[TBL] [Abstract][Full Text] [Related]
10. Commercial Opportunities and Ethical Pitfalls in Personalized Medicine: A Myriad of Reasons to Revisit the Myriad Genetics Saga.
So D; Joly Y
Curr Pharmacogenomics Person Med; 2013 Jun; 11(2):98-109. PubMed ID: 23885284
[TBL] [Abstract][Full Text] [Related]
11. Myriad and the mass media: the covering of a gene patent controversy.
Caulfield T; Bubela T; Murdoch CJ
Genet Med; 2007 Dec; 9(12):850-5. PubMed ID: 18091435
[TBL] [Abstract][Full Text] [Related]
12. Human gene patents: the possible impacts on genetic services healthcare.
Walpole IR; Dawkins HJ; Sinden PD; O'Leary PC
Med J Aust; 2003 Aug; 179(4):203. PubMed ID: 12914511
[TBL] [Abstract][Full Text] [Related]
13. The History of Patenting Genetic Material.
Sherkow JS; Greely HT
Annu Rev Genet; 2015; 49():161-82. PubMed ID: 26442843
[TBL] [Abstract][Full Text] [Related]
14. European opposition to exclusive control over predictive breast cancer testing and the inherent implications for U.S. patent law and public policy: a case study of the Myriad Genetics' BRCA patent controversy.
Paradise J
Food Drug Law J; 2004; 59(1):133-54. PubMed ID: 15190928
[No Abstract] [Full Text] [Related]
15. Move to patent cancer gene touches off storm of protest.
Lewin T
N Y Times Web; 1996 May; ():A14. PubMed ID: 11647105
[No Abstract] [Full Text] [Related]
16. European groups oppose Myriad's latest patent on BRCA1.
Benowitz S
J Natl Cancer Inst; 2003 Jan; 95(1):8-9. PubMed ID: 12509391
[No Abstract] [Full Text] [Related]
17. Actor-network theory: a tool to support ethical analysis of commercial genetic testing.
Williams-Jones B; Graham JE
New Genet Soc; 2003 Dec; 22(3):271-96. PubMed ID: 15115034
[TBL] [Abstract][Full Text] [Related]
18. The impact of patents on the development of genome-based clinical diagnostics: an analysis of case studies.
Pierce BL; Carlson CS; Kuszler PC; Stanford JL; Austin MA
Genet Med; 2009 Mar; 11(3):202-9. PubMed ID: 19367193
[TBL] [Abstract][Full Text] [Related]
19. Constructing narratives of heroism and villainy: case study of Myriad's BRACAnalysis(®) compared to Genentech's Herceptin(®).
Baldwin AL; Cook-Deegan R
Genome Med; 2013; 5(1):8. PubMed ID: 23369278
[TBL] [Abstract][Full Text] [Related]
20. [Opposition to Myriad Genetics patents and their total or partial revocation in Europe: early conclusions].
Cassier M; Stoppa-Lyonnet D
Med Sci (Paris); 2005; 21(6-7):658-62. PubMed ID: 15985212
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
